93439-79-3

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-methoxyphenyl)-1H-pyrazol-5-amine(SALTDATA: FREE) is used as a potential pharmaceutical candidate for the development of new drugs due to its possible biological activity and structural properties that may contribute to therapeutic effects.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(4-methoxyphenyl)-1H-pyrazol-5-amine(SALTDATA: FREE) serves as a valuable intermediate or building block for the synthesis of more complex organic compounds, potentially leading to the creation of novel molecules with specific applications.

Upstream product

• 14271-83-1 4-methoxybenzoyl cyanide 
• 35070-82-7 2-(4-methoxyphenyl)-3-oxopropanenitrile 
• 104-47-2 p-methoxybenzylnitrile 

Downstream Products

• 1026670-61-0 C₂₉H₃₃N₇O₄S 
• 1448466-71-4 1,3-dihydro-8-(4-methoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one 
• 1404447-08-0 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1448466-55-4 1,3-dihydro-8-(4-methoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione 
• 79441-94-4 8-(4-Methoxy-phenyl)-4-(4-nitro-phenyl)-pyrazolo[5,1-c][1,2,4]triazine 

Relevant academic research and scientific papers

A new, one-pot, multicomponent synthesis of 5-aza-9-deaza-adenines under microwave irradiation

A new, practical, three-component method for the synthesis of 5-aza-9-deaza-adenines is developed. Aminopyrazoles react in a one-pot fashion with triethyl orthoformate and cyanamide under microwave irradiation affording 5-aza-9-deaza-adenines in good yiel

Structure and tautomerism of 4-substituted 3(5)-aminopyrazoles in solution and in the solid state: NMR study and Ab initio calculations

Annular tautomerism of 3(5)-aminopyrazoles containing a cyano, thiocyanato, or aryl substituent in the 4-position has been studied by 1H and 13C NMR in solution, cross-polarization and magic-angle spinning 13C NMR in the s

Study of regioselectivity of reactions between 3(5)-aminopyrazoles and 2-acetylcycloalkanones

Regioselectivity was examined of reactions between nine 3(5)-aminopyrazoles and 2-acetylcyclopentanone and 2-acetylcyclohexanone under various conditions. A series of cyclopenta[e]pyrazolo-[1,5-a]pyrimidines was obtained. The highest regioselectivity of the reaction was observed in alcohol at 20°C in the presence of a catalytic quantity of trifl uoroacetic acid. The regiostructure of compounds was established by 1H and 13C NMR spectroscopy. Pleiades Publishing, Ltd., 2012.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders

The invention relates to methods of using the compounds of the invention, including pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof, as well as pharmaceutical compositions comprising the same, in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders. The invention also relates to modulating the activity of an Eph receptor in a cell, stimulating neural regeneration, and reversing neuronal degeneration, by administering a compound of the invention to a cell or subject in an effective amount.

Organic compounds

The invention relates to the use of pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof in the treatment of kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds, and a process for the preparation of the novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds.

PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof in the treatment of kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds, and a process for the preparation of the novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds.